Substantial Prevalence of Chronic Diseases will Escalate the European Peptide Therapeutics Market

Published: Nov 2020

The European peptide therapeutics market will see a considerable growth of 4.3% during the forecast period. The region has a significant presence of peptide therapeutics industry players, with extensive R&D in the market. With the increase in the number of cases of cancer in the region, the demand for proper treatment and availability of drugs is expected to rise; thereby, augmenting the growth of peptide therapeutics for cancer treatment. 

Moreover, well-developed healthcare infrastructure is also estimated to surge the adoption of various healthcare facilities in the region. Further, the surging need for early disease diagnosis in the region is supporting the growth of the peptide therapeutics market.

Browse the full report description of "European Peptide Therapeutics Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Parenteral), by Application (Cancer, Metabolic Disorder, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/european-peptide-therapeutics-market

Another factor that encourages the growth of the market includes the rising mortality rate from respiratory disorders across the region. As per the Organization For Economic Co-Operation and Development, the self-reported COPD and asthma rates were 4.0% and 6.1% respectively in European Union countries. 

Moreover, it has been found that the prevalence rate of diseases is higher in women as compared to men. As per the OECD 2019, respiratory diseases are a major cause of death accounting for 10% of deaths across all OECD countries. COPD accounted for 4% of all deaths globally. Smoking is the main factor that leads to COPD, and occupational exposure to dust, fumes, and chemicals, and air pollution, in general, are also important risk factors. Thus, rising mortalities due to respiratory disorders create a scope for the growth of the market over the forecast period.

Market Coverage


Report Elements

Details

Study Period

2019-2026

Base year

2019

Forecast period

2020-2026

Segments Covered

By Route of Administration and By Application

Countries Covered

UK, Germany, Italy, France, Spain, Rest of Europe

Key Companies Profiled

Novo Nordisk A/S, Eli Lilly & Co., AstraZeneca Plc, CordenPharma International GmbH, Bachem Holding AG, and Sanofi SA

Key questions addressed by the report

  • What is the market growth rate during the forecast period?
  • Which segment/region dominates the market in the base year?
  • Which segment/region will project the fastest growth in the market during the forecast period?
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

European Peptide Therapeutics Market – Segmentation

By Route of Administration

  • Oral
  • Parenteral

By Application

  • Cancer
  • Metabolic Disorder
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Respiratory Disorders
  • Others (Kidney Disorder and Autoimmune Disorder)

European Peptide Therapeutics Market – Segmentation by Geography

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/european-peptide-therapeutics-market